Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
The Journal of Biological Chemistry
|
April 21, 2010
Phosphate-induced apoptosis of hypertrophic chondrocytes is associated with a decrease in mitochondrial membrane potential and is dependent upon Erk1/2 phosphorylation
Susanne U Miedlich, Alena Zalutskaya, Eric D Zhu, et al.
Endocrinology
|
July 25, 2014
Phosphate interacts with PTHrP to regulate endochondral bone formation
Eva S Liu, Alena Zalutskaya, Byongsoo Timothy Chae, et al.
Molecular Cancer Therapeutics
|
October 14, 2025
Dabogratinib (TYRA-300), an FGFR3 isoform-selective inhibitor: preclinical and initial clinical evidence of anti-tumor activity
Jacqueline H Starrett, Eric L Allen, Melissa Neal, et al.
Nature Medicine
|
August 12, 2022
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial
Vivek Subbiah, Philippe A Cassier, Salvatore Siena, et al.
Pharmaceutics
|
October 23, 2020
Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic
Walid Kamoun, Elden Swindell, Christine Pien, et al.
Therapeutic Advances in Medical Oncology
|
October 24, 2024
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer
Sun Min Lim, Stefanie S Schalm, Eun Ji Lee, et al.
Molecular Cancer Therapeutics
|
May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations
Yves A Millet, Alexander I Spira, Christina S Baik, et al.
Thyroid : Official Journal of the American Thyroid Association
|
November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
Future Oncology (London, England)
|
November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study
Frank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.
Journal of Medicinal Chemistry
|
July 15, 2022
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer
Meredith S Eno, Jason D Brubaker, John E Campbell, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
The Journal of Biological Chemistry
|
April 21, 2010
Phosphate-induced apoptosis of hypertrophic chondrocytes is associated with a decrease in mitochondrial membrane potential and is dependent upon Erk1/2 phosphorylation
Susanne U Miedlich, Alena Zalutskaya, Eric D Zhu, et al.
Endocrinology
|
July 25, 2014
Phosphate interacts with PTHrP to regulate endochondral bone formation
Eva S Liu, Alena Zalutskaya, Byongsoo Timothy Chae, et al.
Molecular Cancer Therapeutics
|
October 14, 2025
Dabogratinib (TYRA-300), an FGFR3 isoform-selective inhibitor: preclinical and initial clinical evidence of anti-tumor activity
Jacqueline H Starrett, Eric L Allen, Melissa Neal, et al.
Nature Medicine
|
August 12, 2022
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial
Vivek Subbiah, Philippe A Cassier, Salvatore Siena, et al.
Pharmaceutics
|
October 23, 2020
Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic
Walid Kamoun, Elden Swindell, Christine Pien, et al.
Therapeutic Advances in Medical Oncology
|
October 24, 2024
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer
Sun Min Lim, Stefanie S Schalm, Eun Ji Lee, et al.
Molecular Cancer Therapeutics
|
May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations
Yves A Millet, Alexander I Spira, Christina S Baik, et al.
Thyroid : Official Journal of the American Thyroid Association
|
November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
Future Oncology (London, England)
|
November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study
Frank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.
Journal of Medicinal Chemistry
|
July 15, 2022
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer
Meredith S Eno, Jason D Brubaker, John E Campbell, et al.
Page
of 1